atorvastatin has been researched along with oxazolidin-2-one in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Bloomfield, D; Carlson, GL; Littlejohn, TW; McKenney, JM; Mitchel, Y; Pasternak, RC; Sapre, A; Sisk, CM; Tribble, D | 1 |
| Bergman, AJ; Dockendorf, MF; Dykstra, K; Green, M; Krishna, R; Wagner, JA | 1 |
| Jialal, I; Kaur, J | 1 |
| Kikuchi, M; McCrary Sisk, C; Nakagomi, M; Numaguchi, H; Shirakawa, M; Surks, HK; Tamura, S; Teramoto, T | 1 |
| Havekes, LM; Jukema, JW; Kühnast, S; Landmesser, U; Lüscher, TF; Pieterman, E; Princen, HM; Rensen, PC; Simic, B; van der Hoorn, JW; van der Tuin, SJ; van Klinken, JB; Willems van Dijk, K | 1 |
| Baer, AL; deGoma, EM; Donovan, DS; Dunbar, RL; Ginsberg, HN; Gutstein, DE; Holleran, S; Johnson-Levonas, AO; Jumes, P; Karmally, W; Lassman, ME; Liu, Y; Millar, JS; Obunike, J; Pollan, L; Rader, DJ; Rafeek, H; Ramakrishnan, R; Reyes-Soffer, G; Tohyama, J; Wagner, JA | 1 |
| Bowman, L; Braunwald, E; Cannon, CP; Chen, F; Collins, R; Hopewell, JC; Landray, MJ; Sammons, E; Stevens, W; Valdes- Marquez, E; Wallendszus, K; Wiviott, S | 1 |
| Aburatani, T; Hashimoto, R; Ishihara, H; Masuda, Y; Matschiner, G; Miyauchi, R; Nagano, Y; Nagatomo, K; Nara, F; Nishizawa, T; Okuno, K; Suzuki, C; Suzuki, E; Takahashi, T; Yamaguchi, S; Yamamura, N | 1 |
| Filardi, PP; Maggioni, AP | 1 |
| Adam, S; Durrington, PN; Soran, H | 1 |
| Angermann, C; Armitage, J; Baigent, C; Barter, P; Baxter, A; Blaustein, R; Bowman, L; Braunwald, E; Brenner, S; Cannon, C; Chen, F; Chen, Y; Chen, Z; Collins, R; Dayanandan, R; DeLucca, P; Ertl, G; Fabbri, G; Fajardo-Moser, M; Goodenough, R; Goto, S; Gray, A; Hao, D; Haynes, R; Herrington, W; Hill, M; Hopewell, JC; Knott, C; Landray, M; Lay, M; Liu, J; Lucci, D; Macdonnell, S; Maggioni, A; Mihaylova, B; Mitchel, Y; Mosegaard, S; Murphy, K; Sammons, E; Stevens, W; Tobert, J; Valdes-Marquez, E; Wallendszus, K; Wanner, C; Wincott, E; Wiviott, S; Wuhan, B; Zhang, H | 1 |
1 review(s) available for atorvastatin and oxazolidin-2-one
| Article | Year |
|---|---|
Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiology; Cardiovascular Diseases; Cholesterol, LDL; Europe; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Oxazolidinones; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Factors; United Kingdom; United States | 2018 |
5 trial(s) available for atorvastatin and oxazolidin-2-one
| Article | Year |
|---|---|
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol Ester Transfer Proteins; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Middle Aged; Oxazolidinones; Pyrroles; Treatment Outcome | 2009 |
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol Ester Transfer Proteins; Dose-Response Relationship, Drug; Double-Blind Method; Dyslipidemias; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Japan; Male; Middle Aged; Oxazolidinones; Patient Safety; Pyrroles; Time Factors; Treatment Outcome; Young Adult | 2013 |
Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein B-100; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Oxazolidinones; Pyrroles; Time Factors; Triglycerides | 2015 |
Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, a
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intention to Treat Analysis; Male; Middle Aged; Oxazolidinones; Research Design | 2017 |
Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.
Topics: Adult; Atherosclerosis; Atorvastatin; Double-Blind Method; Humans; Myocardial Infarction; Oxazolidinones; Treatment Outcome | 2022 |
5 other study(ies) available for atorvastatin and oxazolidin-2-one
| Article | Year |
|---|---|
Model-based development of anacetrapib, a novel cholesteryl ester transfer protein inhibitor.
Topics: Anticholesteremic Agents; Atorvastatin; Biological Availability; Capsules; Cholesterol Ester Transfer Proteins; Computer Simulation; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Drug Design; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Models, Biological; Nonlinear Dynamics; Oxazolidinones; Pyrroles; Tablets | 2011 |
The cholesterol ester transfer protein inhibitor, anacetrapib.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Drug Therapy, Combination; Heptanoic Acids; Humans; Oxazolidinones; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Disease Progression; Drug Combinations; Female; Heptanoic Acids; Mice, Transgenic; Oxazolidinones; Pyrroles; Serum Amyloid A Protein | 2015 |
Generation and Characterization of a Novel Small Biologic Alternative to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Antibodies, DS-9001a, Albumin Binding Domain-Fused Anticalin Protein.
Topics: Albumins; Animals; Atorvastatin; Cholesterol Ester Transfer Proteins; Drug Interactions; Hep G2 Cells; Humans; Lipocalins; Lipoproteins, LDL; Macaca fascicularis; Male; Mice; Oxazolidinones; Proprotein Convertase 9; Protein Domains; Rats; Rats, Sprague-Dawley; Receptors, LDL; Recombinant Fusion Proteins | 2018 |
[The REVEAL study].
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Oxazolidinones; Randomized Controlled Trials as Topic; Treatment Outcome | 2018 |